

# **Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline Review, H2 2019**

<https://marketpublishers.com/r/C7BAAB74448EN.html>

Date: December 2019

Pages: 255

Price: US\$ 2,000.00 (Single User License)

ID: C7BAAB74448EN

## **Abstracts**

Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline Review, H2 2019

### **SUMMARY**

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Clostridium difficile Infections - Pipeline Review, H2 2019, provides an overview of the Clostridium difficile Infections (Infectious Disease) pipeline landscape.

Clostridium difficile infections are caused by Clostridium difficile, often called C. difficile or C. diff, a bacterium that can cause symptoms ranging from diarrhea to life-threatening inflammation of the colon. Symptoms of C. diff infection includes watery diarrhea, with abdominal pain or tenderness, loss of appetite, fever, blood or pus in the stool and weight loss. Risk factors are age, surgery of the gastrointestinal (GI) tract, a weakened immune system, kidney disease, use of drugs called proton-pump inhibitors, which lessen stomach acid and use of chemotherapy drugs. This condition may be controlled by the use of medication such as antibiotics and may be prevented by lifestyle modification.

### **REPORT HIGHLIGHTS**

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Clostridium difficile Infections - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Clostridium difficile Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the

descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Clostridium difficile Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Clostridium difficile Infections (Clostridium difficile Associated Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 4, 10, 11, 39, 17 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 7 molecules, respectively.

Clostridium difficile Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Clostridium difficile Infections (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Clostridium difficile Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration

details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Clostridium difficile Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Clostridium difficile Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Clostridium difficile Infections (Infectious Disease)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Clostridium difficile Infections (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Clostridium difficile Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

Introduction

Clostridium difficile Infections (Clostridium difficile Associated Disease) - Overview

Clostridium difficile Infections (Clostridium difficile Associated Disease) - Therapeutics Development

Clostridium difficile Infections (Clostridium difficile Associated Disease) - Therapeutics Assessment

Clostridium difficile Infections (Clostridium difficile Associated Disease) - Companies Involved in Therapeutics Development

Clostridium difficile Infections (Clostridium difficile Associated Disease) - Drug Profiles

Clostridium difficile Infections (Clostridium difficile Associated Disease) - Dormant Projects

Clostridium difficile Infections (Clostridium difficile Associated Disease) - Discontinued Products

Clostridium difficile Infections (Clostridium difficile Associated Disease) - Product Development Milestones

Appendix

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Clostridium difficile Infections (Clostridium difficile Associated Disease), H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Clostridium difficile Infections (Clostridium difficile Associated Disease) - Dormant Projects, H2 2019

Clostridium difficile Infections (Clostridium difficile Associated Disease) - Dormant Projects, H2 2019 (Contd..1), H2 2019

Clostridium difficile Infections (Clostridium difficile Associated Disease) - Dormant Projects, H2 2019 (Contd..2), H2 2019

Clostridium difficile Infections (Clostridium difficile Associated Disease) - Dormant Projects, H2 2019 (Contd..3), H2 2019

Clostridium difficile Infections (Clostridium difficile Associated Disease) - Discontinued Products, H2 2019

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Clostridium difficile Infections (Clostridium difficile Associated Disease), H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Number of Products by Top 10 Targets, H2 2019

Number of Products by Stage and Top 10 Targets, H2 2019

Number of Products by Top 10 Mechanism of Actions, H2 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Top 10 Routes of Administration, H2 2019

Number of Products by Top 10 Molecule Types, H2 2019

Number of Products by Stage and Top 10 Molecule Types, H2 2019

### COMPANIES MENTIONED

Absynth Biologics Ltd

Acurx Pharmaceuticals LLC

Akthelia Pharmaceuticals Ltd

Appili Therapeutics Inc

Aviex Technologies LLC

AzurRx BioPharma Inc

Biomica

Botanix Pharmaceuticals Ltd

Boulos and Cooper Pharmaceuticals Pty Ltd

Chain Biotechnology Ltd

Crestone Inc

CSA Biotechnologies LLC

Daiichi Sankyo Co Ltd

Deinove SAS

Enterobiotix Ltd

Facile Therapeutics Inc

Ferring International Center SA

Finch Therapeutics Group

Fzata Inc

GlaxoSmithKline Plc

Immune Biosolutions Inc  
ImmuneBiotech AB  
ImmuniMed Inc  
ImmunoBiology Ltd  
Immuron Ltd  
Inositec AG  
Inovio Pharmaceuticals Inc  
Inspyr Therapeutics Inc  
Integrated BioTherapeutics Inc  
Kaleido Biosciences Inc  
KamTek Inc  
KoBioLabs Inc  
Locus Biosciences Inc  
Mapp Biopharmaceutical Inc  
Matrivax Research & Development Corp  
Merck & Co Inc  
MGB Biopharma Ltd  
Microbiotica Ltd  
Micropharm Ltd  
Miyarisan Pharmaceutical Company Ltd  
MyBiotics Pharma Ltd  
Novabiotics Ltd  
NovoBiotic Pharmaceuticals LLC  
Nubiyota LLC  
Oragenics Inc  
Otsuka Holdings Co Ltd  
PanTheryx Inc  
Pfizer Inc  
Procarta Biosystems Ltd  
Proxi Biotech IVS  
Pylum Biosciences Inc  
Q2 Pharma Ltd  
QureTech Bio AB  
Recursion Pharmaceuticals Inc  
Rise Therapeutics LLC  
SciBac Inc  
Scioto Biosciences Inc  
Seres Therapeutics Inc  
Serometrix LLC



Servatus Ltd  
Summit Therapeutics Plc  
Symbiotic Health Inc  
Synthetic Biologics Inc  
Valevia UK Ltd  
Valneva SE  
Vedanta Biosciences Inc  
Vitality Biopharma Inc  
XBiotech Inc

## I would like to order

Product name: Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/C7BAAB74448EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C7BAAB74448EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

